NTC has shared positive results from the Phase II MIRAKLE study evaluating the efficacy and tolerability of NTC014 (quinolone antibiotic + NSAID in eye drops solution) in the treatment of bacterial conjunctivitis in adults. 

The results show the non-inferiority of NTC014 eye drops vs. antibiotic alone in microbiological eradication, with unexpected efficacy results even against pathogens classified as Intermediate or resistant to the quinolone antibiotic under study. 

“These interim findings reaffirm that NTC014 is eligible to be a new treatment for bacterial conjunctivitis,” said Alessandro Colombo, Chief Scientific Officer, NTC. “We aim at demonstrating with robust clinical evidence value and potential for NTC014, considering also that this drug responds to our mission to contribute to fighting antibiotic resistance by using less antibiotics, for a shorter treatment duration with no limitation of usage, also in case of non-confirmation of bacterial aetiology.” 

NTC has already successfully developed and launched the first combination of a quinolone and steroid for post cataract surgery, licensed in almost 90 countries and currently marketed in 60 countries, in Europe, Asia, Americas and Africa. 

“We are encouraged by the overall results of the Mirakle study,” added Riccardo Carbucicchio, Chief Executive Officer in NTC, “NTC014 is first in class combination worldwide of an antibiotic and an NSAID. Given the significant unmet medical need, NTC014 aims to provide physicians with an effective treatment for moderate-severe bacterial conjunctivitis, a common eye infection. We believe that NTC014 has a great potential and we aim to finalise the commercial partnering for this asset in most countries of the world before end of 2025.”

Diana Spencer, Senior Digital Content Editor, DDW